Advertisement

Pathological Distinction of Pulmonary Large Cell Neuroendocrine Carcinoma from Small-Cell Lung Carcinoma Using Immunohistochemistry

  • Kenzo Hiroshima
Part of the Methods of Cancer Diagnosis, Therapy, and Prognosis book series (HAYAT, volume 2)

For many years, only two major categories of pulmonary neuroendocrine tumors were recognized: the carcinoid tumor and smallcell lung carcinoma (SCLC). In 1972, Arrigoni et al. (1972) proposed pathologic criteria for the atypical carcinoid tumor. Atypical carcinoids have more evident cytologic atypia, cellularity, focal necrosis, and increased mitotic activity (between 5 and 10 mitoses per 10 high-power fields) than typical carcinoid tumors, and the clinical aggressiveness of atypical carcinoid is less than that of SCLC. Since then, neuroendocrine tumors of the lung have been classified into three categories: typical carcinoid, atypical carcinoid, and SCLC. In recent years, it has become apparent that a large variety of pulmonary neuroendocrine tumors exist and that some tumors cannot be easily classified into one of these three categories. Several new categories have been proposed such as neuroendocrine carcinoma of intermediate sized cells, largecell neuroendocrine tumor of the lung, peripheral small-cell carcinoma of the lung resembling carcinoid tumor, and nonsmall cell lung carcinoma (NSCLC) with neuroendocrine features. In 1991, large cell neuroendocrine carcinoma (LCNEC) was proposed for the fourth high-grade neuroendocrine tumor of the lung (Travis et al., 1991).

Keywords

Neuroendocrine Tumor Carcinoid Tumor Neuroendocrine Carcinoma Large Cell Carcinoma Atypical Carcinoid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Araki, K., Ishii, G., Yokose, T., Nagai, K., Funai, K., Kodama, K., Nishiwaki, Y., and Ochiai, A. 2003. Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. Lung Cancer 40: 173–180PubMedCrossRefGoogle Scholar
  2. Arrigoni, M.G., Woolner, L.B., and Bernatz, P.E. 1972. Atypical carcinoid tumors of the lung. J. Thorac. Cardiovasc. Surg. 64: 413–421PubMedGoogle Scholar
  3. Asamura, H., Kameya, T., Matsuno, Y., Noguchi, M., Tada, H., Ishikawa, Y., Yokose, T., Jiang, S.X., Inoue, T., Nakagawa, K., Tajima, K., and Nagai, K. 2006. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J. Clin. Oncol. 24: 70–76PubMedCrossRefGoogle Scholar
  4. Broers, J.L., Rot, M.K., Oostendorp, T., Huysmans, A., Wagenaar, S.S., Wiersma-van Tilburg, A.J., Vooijs, G.P., and Ramaekers, F.C. 1987. Immunocytochemical detection of human lung cancer heterogeneity using antibodies to epithelial, neuronal, and neuroendocrine antigens. Cancer Res. 47: 3225–3234PubMedGoogle Scholar
  5. Casali, C., Stefani, A., Rossi, G., Migaldi, M., Bettelli, S., Parise, A., and Morandi, U. 2004. The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung. Ann. Thorac. Surg. 77: 247–252PubMedCrossRefGoogle Scholar
  6. Dresler, C.M., Ritter, J.H., Patterson, G.A., Ross, E., Bailey, M.S., and Wick, M.R. 1997. Clinical-pathologic analysis of 40 patients with large cell neuroendocrine carcinoma of the lung. Ann. Thorac. Surg. 63: 180–185PubMedCrossRefGoogle Scholar
  7. Folpe, A.L., Gown, A.M., Lamps, L.W., Garcia, R., Dail, D.H., Zarbo, R.J., and Schmidt, R.A. 1999. Thyroid transcription factor-1: immuno-histochemical evaluation in pulmonary neuroen-docrine tumors. Mod. Pathol. 12: 5–8PubMedGoogle Scholar
  8. Govindan, R., Page, N., Morgensztern, D., Read, W., Tierney, R., Vlahiotis, A., Spitznagel, E.L., and Piccirillo, J. 2006. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J. Clin. Oncol. 24: 4539–4544PubMedCrossRefGoogle Scholar
  9. Gugger, M., Burckhardt, E., Kappeler, A., Hirsiger, H., Laissue, J.A., and Mazzucchelli, L. 2002. Quantitative expansion of structural genomic alterations in the spectrum of neuroendocrine lung carcinomas. J. Pathol. 196: 408–415PubMedCrossRefGoogle Scholar
  10. Guinee, D.G. Jr, Fishback, N.F., Koss, M.N., Abbondanzo, S.L., and Travis, W.D. 1994. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am. J. Clin. Pathol. 102: 406–414PubMedGoogle Scholar
  11. Hiroshima, K., Iyoda, A., Shibuya, K., Haga, Y., Toyozaki, T., Iizasa, T., Nakayama, T., Fujisawa, T., and Ohwada, H. 2004. Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma. Cancer 100: 1190–1198PubMedCrossRefGoogle Scholar
  12. Hiroshima, K., Iyoda, A., Shida, T., Shibuya, K., Iizasa, T., Kishi, H., Tanizawa, T., Fujisawa, T., and Nakatani, Y. 2006. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immu-nohistochemical, and molecular analysis. Mod. Pathol. 19: 1358–1368PubMedCrossRefGoogle Scholar
  13. Iyoda, A., Hiroshima, K., Toyozaki, T., Haga, Y., Fujisawa, T., and Ohwada, H. 2001a. Clinical characterization of pulmonary large cell neu-roendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 91: 1992–2000CrossRefGoogle Scholar
  14. Iyoda, A., Hiroshima, K., Toyozaki, T., Haga, Y., Baba, M., Fujisawa, T., and Ohwada, H. 2001b. Adjuvant chemotherapy for large cell carcinoma with neuroendocrine features. Cancer 92: 1108–1112CrossRefGoogle Scholar
  15. Iyoda, A., Hiroshima, K., Baba, M., Saitoh, Y., Ohwada, H., and Fujisawa, T. 2002. Pulmonary large cell carcinomas with neuroendocrine features are high-grade neuroendocrine tumors. Ann. Thorac. Surg. 73: 1049–1054PubMedCrossRefGoogle Scholar
  16. Iyoda, A., Hiroshima, K., Moriya, Y., Sekine, Y., Shibuya, K., Iizasa, T., Nakatani, Y., and Fujisawa, T. 2006a. Prognostic impact of large cell neuroen-docrine histology in patients with pathologic stage Ia pulmonary non-small cell carcinoma. J. Thorac. Cardiovasc. Surg. 132: 312–315CrossRefGoogle Scholar
  17. Iyoda, A., Hiroshima, K., Moriya, Y., Takiguchi, Y., Sekine, Y., Shibuya, K., Iizasa, T., Kimura, H., Nakatani, Y., and Fujisawa, T. 2006b. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann. Thorac. Surg. 82: 1802–1807CrossRefGoogle Scholar
  18. Iyoda, A., Hiroshima, K., Nakatani, Y., and Fujisawa, T. 2007. Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma. Ann. Thorac. Surg. 84: 702–707PubMedCrossRefGoogle Scholar
  19. Jerome Marson, V., Mazieres, J., Groussard, O., Garcia, O., Berjaud, J., Dahan, M., Carles, P., and Daste, G. 2004. Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: correlation with histological type and grade. Histopathology 45: 125–134PubMedCrossRefGoogle Scholar
  20. Jiang, S.X., Kameya, T., Sato, Y., Yanase, N., Yoshimura, H., and Kodama, T. 1996. Bcl-2 pro-tein expression in lung cancer and close correlation with neuroendocrine differentiation. Am. J. Pathol. 148: 837–846PubMedGoogle Scholar
  21. Jiang, S.X., Kameya, T., Shinada, J., and Yoshimura, H. 1999. The significance of frequent and independent p53 and bcl-2 expression in large-cell neuroendocrine carcinomas of the lung. Mod. Pathol. 12: 362–369PubMedGoogle Scholar
  22. Jiang, S.X., Kameya, T., Asamura, H., Umezawa, A., Sato, Y., Shinada, J., Kawakubo, Y., Igarashi, T., Nagai, K., and Okayasu, I. 2004. hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendo-crine tumors. Mod. Pathol. 17: 222–229PubMedCrossRefGoogle Scholar
  23. Jones, M.H., Virtanen, C., Honjoh, D., Miyoshi, T., Satoh, Y., Okumura, S., Nakagawa, K., Nomura, H., and Ishikawa, Y. 2004. Two prognostically significant subtypes of high-grade lung neuroen-docrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 363: 775–781PubMedCrossRefGoogle Scholar
  24. Kaufmann, O., and Dietel, M. 2000. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology 36: 415–420PubMedCrossRefGoogle Scholar
  25. Kontogianni, K., Nicholson, A.G., Butcher, D., and Sheppard, M.N. 2005. CD56: a useful tool for the diagnosis of small cell lung carcinomas on biopsies with extensive crush artefact. J. Clin. Pathol. 58: 978–980PubMedCrossRefGoogle Scholar
  26. Marchevsky, A.M., Gal, A.A., Shah, S., and Koss, M.N. 2001. Morphometry confirms the presence of considerable nuclear size overlap between “small cells” and “large cells” in high-grade pulmonary neuroendocrine neoplasms. Am. J. Clin. Pathol. 116: 466–472PubMedCrossRefGoogle Scholar
  27. Nicholson, S.A., Beasley, M.B., Brambilla, E., Hasleton, P.S., Colby, T.V., Sheppard, M.N., Falk, R., and Travis, W.D. 2002. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am. J. Surg. Pathol. 26: 1184–1197PubMedCrossRefGoogle Scholar
  28. Nitadori, J., Ishii, G., Tsuta, K., Yokose, T., Murata, Y., Kodama, T., Nagai, K., Kato, H., and Ochiai, A. 2006. Immunohistochemical differential diagnosis between large cell neuroen-docrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel. Am. J. Clin. Pathol. 125: 682–692PubMedCrossRefGoogle Scholar
  29. Onuki, N., Wistuba, I.I., Travis, W.D., Virmani, A.K., Yashima, K., Brambilla, E., Hasleton, P., and Gazdar, A.F. 1999. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 85: 600–607PubMedCrossRefGoogle Scholar
  30. Pelosi, G., Masullo, M., Leon, M.E., Veronesi, G., Spaggiari, L., Pasini, F., Sonzogni, A., Iannucci, A., Bresaola, E., and Viale, G. 2004. CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas. Virchows Arch. 445: 449–455PubMedCrossRefGoogle Scholar
  31. Pelosi, G., Rodriguez, J., Viale, G., and Rosai, J. 2005. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am. J. Surg. Pathol. 29: 179–187PubMedCrossRefGoogle Scholar
  32. Peng, W.X., Shibata, T., Katoh, H., Kokubu, A., Matsuno, Y., Asamura, H., Tsuchiya, R., Kanai, Y., Hosoda, F., Sakiyama, T., Ohki, M., Imoto, I., Inazawa, J., and Hirohashi, S. 2005. Array-based comparative genomic hybridization analysis of high-grade neuroendocrine tumors of the lung. Cancer Sci. 96: 661–667PubMedCrossRefGoogle Scholar
  33. Przygodzki, R.M., Finkelstein, S.D., Langer, J.C., Swalsky, P.A., Fishback, N., Bakker, A., Guinee, D.G., Koss, M., and Travis, W.D. 1996. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neu-roendocrine tumors. Correlation with histologi-cal subtype and clinical outcome. Am. J. Pathol. 148: 1531–1541PubMedGoogle Scholar
  34. Rossi, G., Cavazza, A., Marchioni, A., Longo, L., Migaldi, M., Sartori, G., Bigiani, N., Schirosi, L., Casali, C., Morandi, U., Facciolongo, N., Maiorana, A., Bavieri, M., Fabbri, L.M., and Brambilla, E. 2005. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendo-crine carcinoma of the lung. J. Clin. Oncol. 23: 8774–8785PubMedCrossRefGoogle Scholar
  35. Rusch, V.W., Klimstra, D.S., and Venkatraman, E.S. 1996. Molecular markers help characterize neuroendocrine lung tumors. Ann. Thorac. Surg. 62: 798–810PubMedCrossRefGoogle Scholar
  36. Sekido, Y., Obata, Y., Ueda, R., Hida, T., Suyama, M., Shimokata, K., Ariyoshi, Y., and Takahashi, T. 1991. Preferential expression of c-kit pro-tooncogene transcripts in small cell lung cancer. Cancer Res. 51: 2416–2419PubMedGoogle Scholar
  37. Sturm, N., Rossi, G., Lantuejoul, S., Papotti, M., Frachon, S., Claraz, C., Brichon, P.Y., Brambilla, C., and Brambilla, E. 2002. Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum. Pathol. 33: 175–182PubMedCrossRefGoogle Scholar
  38. Takei, H., Asamura, H., Maeshima, A., Suzuki, K., Kondo, H., Niki, T., Yamada, T., Tsuchiya, R., and Matsuno, Y. 2002. Large cell neuroen-docrine carcinoma of the lung: a clinicopatho-logic study of eighty-seven cases. J. Thorac. Cardiovasc. Surg. 124: 285–292PubMedCrossRefGoogle Scholar
  39. Travis, W.D., Linnoila, R.I., Tsokos, M.G., Hitchcock, C.L., Cutler, G.B. Jr, Nieman, L., Chrousos, G., Pass, H., and Doppman, J. 1991. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. Am. J. Surg. Pathol. 15: 529–553PubMedCrossRefGoogle Scholar
  40. Travis, W.D., Gal, A.A., Colby, T.V., Klimstra, D.S., Falk, R., and Koss, M.N. 1998. Reproducibility of neuroendocrine lung tumor classification. Hum. Pathol. 29: 272–279PubMedCrossRefGoogle Scholar
  41. Ullmann, R., Petzmann, S., Sharma, A., Cagle, P.T., and Popper, H.H. 2001. Chromosomal aberrations in a series of large-cell neuroendo-crine carcinomas: unexpected divergence from small-cell carcinoma of the lung. Hum. Pathol. 32: 1059–1063PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V 2008

Authors and Affiliations

  1. 1.Kenzo Hiroshima, Department of Diagnostic Pathology, Graduate School of MedicineChiba UniversityChuo-kuJapan

Personalised recommendations